natgillin/translations-raw huggingface dataset:
As part of this plan, the Marketing Authorisation Holder will provide health care professionals with educational materials for healthcare professionals and patients that are aimed at risk minimisation and will support safe and effective use for the product by the patient. 
V okviru tega načrta bo imetnik dovoljenja za promet z zdravilom zdravnikom posredoval izobraževalna gradiva za zdravnike in bolnike.
Do not use three 1 mg blisters in place of one 3 mg blister, as this will give you a much higher dose of insulin. 
Namesto enega 3-mg pretisnega omota ne smete uporabiti treh 1-mg pretisnih omotov, ker boste v tem primeru dobili veliko večji odmerek insulina.
The effect of renal impairment on the absorption of inhaled human insulin has not been studied (see section 4.2). 
Učinka ledvičnih okvar na absorpcijo humanega insulina za inhaliranje niso proučevali (glejte poglavje 4.2).
Administration of fluticasone prior to EXUBERA does not appear to affect insulin absorption (see section 5.2). 
Uporaba flutikazona pred EXUBERO ne vpliva na absorpcijo insulina (glejte poglavje 5.2).
6 of these discontinued subjects underwent follow-up pulmonary function testing. 
Pri šestih bolnikih od tistih, s katerimi so sodelovanje v študiji prekinili, so s spremljanjem pljučne funkcije nadaljevali.
One blister card contains 6 perforated unit dose blisters (PVC/Aluminium). 
Vsaka ploščica s pretisnimi omoti vsebuje 6 perforiranih pretisnih omotov za enratni odmerek (PVC/aluminij).
In older subjects with type 2 diabetes, inhaled human insulin was absorbed more rapidly than subcutaneously administered fast-acting human insulin. 
Pri starejših bolnikih z diabetesom tipa 2 se je humani insulin za inhaliranje absorbiral hitreje kot subkutano injicirani hitrodelujoči humani insulin.
Development of such antibodies is seen more commonly in patients treated with EXUBERA compared to subcutaneous insulin. 
Razvoj teh protiteles je bolj pogost pri bolnikih, ki so bili zdravljeni z zdravilom EXUBERA, kot s subkutanim insulinom.
Do not substitute three 1 mg blisters for one 3 mg blister. 
Enega 3-mg pretisnega omota ne smete nadomestiti s tremi 1-mg.
Inhaled human insulin, like fast-acting insulin analogues, has a more rapid onset of glucose lowering activity compared to subcutaneously administered soluble human insulin. 
Humani insulin za inhaliranje, podobno kot hitrodelujoči analogi insulina, ima hitrejši nastop aktivnosti zniževanja glukoze kot subkutano aplicirani hitrodelujoči humani insulin.
Your doctor may replace EXUBERA with an injectable insulin for your diabetes. 
Zdravnik vam bo za zdravljenje diabetesa zdravilo EXUBERA morda nadomestil z insulinom za injiciranje.
The new IRU is now locked in place. 
Sedaj je novi nastavek za sproščanje insulina pravilno nameščen na svojem mestu.
• A pack containing 30, 60, 90, 180 and 270 x 1 of 1 mg PVC/Aluminium perforated unit dose 
• pakiranje, ki vsebuje 30, 60, 90, 180 in 270 x 1 1-mg perforiran pretisni omot za enkratni
Your insulin dosage may need to be changed during pregnancy and after giving birth. 
Med nosečnostjo in po porodu bo vaše odmerjanje insulina morda potrebno spremeniti.
Upon regaining consciousness, administration of oral carbohydrate is recommended for the patient in 
Ko se bolniku vrne zavest, je priporočljivo peroralno zaužitje ogljikovih hidratov, s čimer preprečimo
With one hand, squeeze the two chamber release Buttons at the same time on the side of the base while pulling the base all the way out of the 
Z eno roko stisnite oba gumba za sprostitev komore, ki sta ob straneh spodnjega dela inhalatorja, in hkrati z drugo roko povlecite
Patients should avoid exposing the product to high moisture or relative humidity conditions e.g. a steamy bathroom, when taking their dose. 
Bolniki zdravila med uporabo ne smejo izpostaviti zelo vlažnemu okolju oz. okolju z veliko relativno vlažnostjo (npr. kopalnica, polna pare).
See 
Kako
• A pack containing 30, 60, 90, 180 and 270 x 1 of 3 mg PVC/Aluminium perforated unit dose 
• pakiranje, ki vsebuje 30, 60, 90, 180 in 270 x 1 3-mg perforiran pretisni omot za enkratni
There is no experience with EXUBERA in patients with pneumonia. 
Z uporabo EXUBERE pri bolnikih s pljučnico ni izkušenj.
Use of inhaled human insulin is associated with an increase in frequency, and levels of insulin antibodies. 
Uporaba humanega insulina za inhaliranje se kaže z zvečanjem pogostnosti in koncentracije protiteles.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton/Unit dose blisters (30, 60, 90, 180 and 270) 
PODATKI NA ZUNANJI OVOJNINI Škatla / enoodmerni pretisni omoti (30, 60, 90, 180 in 270)
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, 
- Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
Washout Phase 
Faza spiranja
• If you have severe (GOLD stage III or IV), Chronic Obstructive Pulmonary Disease (COPD). 
- če imate hudo kronično obstruktivno pljučno bolezen (KOPB) (stadij III ali IV po GOLD).
In subjects with type 1 or type 2 diabetes, inhaled human insulin has a faster onset of glucose lowering effect in the early hours after dosing when compared with subcutaneously administered fast 
Pri bolnikih z diabetesom tipa 1 ali tipa 2 ima humani insulin za inhaliranje hitrejši nastop učinka glede zniževanja glukoze v prvih urah po odmerku kot subkutano injicirani hitrodelujoči humani
Inhaled Insulin Subcutaneous Insulin 
nastavek za sproščanje insulina insulinski pretisni omot
If you temporarily run out of 3 mg blisters, two 1 mg blisters should be used and you should monitor your blood glucose levels closely. 
Če vam začasno zmanjka 3-mg pretisnih omotov, vzemite dva 1-mg pretisna omota in natančno spremljajte svoj krvni sladkor.
Respiratory 
Dihala
In this case, the Insulin Release Unit (IRU) must be changed prior to the next inhalation (see section 4.4). 
V takšnem primeru je treba nastavek za sproščanje insulina (Insulin release unit - IRU) pred naslednjo inhalacijo zamenjati (glejte poglavje
Keep this leaflet. 
Glejte sliko.
The time to peak insulin concentration (Tmax) is generally half of that for subcutaneously administered fast-acting human insulin. 
Čas do najvišje koncentracije insulina (Tmax) je na splošno za polovico krajši od tistega pri subkutano injiciranem hitrodelujočem humanem insulinu.
Inhaled human insulin may be used alone or in combination with oral antidiabetic agents and/or long or intermediate acting subcutaneously administered insulins to optimise glycaemic control. 
Humani insulin za inhaliranje lahko uporabljamo samega ali v kombinaciji s peroralnimi antidiabetiki in/ali dolgo- ali srednjedolgo- delujočemi subkutano apliciranimi insulini za
A follow-up lung function measurement is recommended after the first 6 months of therapy. 
Po prvih 6 mesecih zdravljenja je priporočljiva ponovna ocena pljučne funkcije.
Do not use three separate 1 mg blisters in place of one 3 mg blister, as this will give you a much higher insulin dose (see “How to take EXUBERA” for further advice). 
Namesto enega 3-mg pretisnega omota ne smete uporabiti treh ločenih 1-mg pretisnih omotov, ker boste v tem primeru dobili veliko večji odmerek insulina (za dodatna navodila glejte ”Kako uporabljati zdravilo EXUBERA“).
Line up the blue line on the top of the IRU with the unlock symbol on the top of the base. 
Poravnajte modro črto na vrhu nastavka za sproščanje insulina s simbolom odklepanja na
If 3 mg blisters are unavailable, use only two 1 mg blisters as replacement. 
Če nimate na voljo 3-mg pretisnega omota, namesto njega uporabite le dva 1-mg.
To use an EXUBERA blister, first separate the blister from the spine by tearing along the tear line 
Pred uporabo pretisnega omota zdravila EXUBERA omot najprej ločite od hrbtišča tako, da ga
QUALITATIVE AND QUANTITATIVE COMPOSITION Each unit dose blister contains 3 mg insulin human. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA En enoodmerni pretisni omot vsebuje 3 mg humanega insulina.
Squeeze the handle until it snaps shut. 
Stisnite ročico, da se bo s tleskom zaprla.
You should avoid taking EXUBERA in moist conditions e.g. a bathroom following a steamy shower as this will usually give you a lower insulin dose than you need (see “Instructions for Use” at the end 
Zdravila EXUBERA ne smete uporabljati v vlažnem okolju, npr. v kopalnici po prhi, ki povzroči veliko pare, saj boste zaradi tega v telo najverjetneje vnesli manjši odmerek insulina, kot ga potrebujete (za nasvet glejte “Navodilo za uporabo insulinskega inhalatorja” na koncu tega navodila).
One percent of patients discontinued EXUBERA 
En odstotek bolnikov je prekinil zdravljenje z zdravilom EXUBERA zaradi kašlja.
For Cmax, the intrasubject variability of inhaled insulin is greater than that of subcutaneously administered fastacting human insulin. 
Intraindividualna variabilnost Cmax inhaliranega insulina je večja kot subkutano apliciranega hitrodelujočega humanega insulina.
For further details on how to use the insulin inhaler refer to the instructions for use (IFU). 
Za nadaljnje podrobnosti o načinu uporabe insulinskega inhalatorja glejte navodila za uporabo Navodilo za uporabo insulinskega inhalatorja).
Small treatment group differences in decline of FEV1 were observed in the EXUBERA group relative to comparator therapy. 
V skupini z zdravilom EXUBERA so v primerjavi s skupino, zdravljeno s primerjalnim zdravilom, opazili majhne razlike v zmanjšanju FEV1 .
For instructions on how to look after your insulin inhaler see “Instructions for Use” at the end of the package leaflet. 
Navodila o tem, kako skrbeti za insulinski inhalator, boste našli v “Navodilu za uporabo insulinskega inhalatorja”, ki se nahaja na koncu tega navodila.
If the 3 mg blister is temporarily unavailable, two 1 mg blisters should be substituted and blood glucose monitored closely. 
Če bolnik trenutno nima na voljo 3-mg pretisnega omota, naj uporabi dva 1-mg pretisna omota in naj natančno nadzira glukozo v krvi.
In clinical trials involving patients with type 2 diabetes not sufficiently controlled with oral agents alone, patients using a regimen of EXUBERA alone or in combination with oral agents, had greater improvements in HbA1c compared with patients treated with oral agents alone. 
V kliničnih preskušanjih na bolnikih z diabetesom tipa 2, pri katerih glikemična kontrola samo s peroralnimi antidiabetiki ni zadostna, se je HbA1c bolj izboljšal pri bolnikih, zdravljenih s shemami z zdravilom EXUBERA samim ali v kombinaciji s peroralnimi antidiabetiki, kot pri bolnikih, zdravljenih samo s peroralnimi antidiabetiki.
Patients in a clinical trial for type 2 diabetes, who used a regimen of EXUBERA in combination with long- or intermediate-acting insulin, had similar changes in HbA1c compared with patients treated 
Bolniki z diabetesom tipa 2, ki so v kliničnem preskušanju uporabljali shemo z zdravilom EXUBERA v kombinaciji z dolgo- ali srednjedolgo-delujočim insulinom, so imeli podobne spremembe HbA1c kot bolniki, zdravljeni samo s subkutanim insulinom.
Observed Change from Baseline in FEV1 (L) in patients with type 1 diabetes mellitus. 
Opažena sprememba FEV1 (L) od izhodišča pri bolnikih z diabetesom mellitusom tipa 1.
Also, read the Patient Information Leaflet for, EXUBERA 1 mg and 3 mg powder for inhalation predispensed. 
Preberite tudi navodilo za uporabo za zdravilo EXUBERA 1 mg in 3 mg prašek za inhaliranje, odmerjen.
If you need dose titrations of less than 1 mg it is recommended you do not use EXUBERA (see section 3 “How to take EXUBERA” for further advice and section 6 “Further information”). 
Če imate nizko telesno maso ali potrebujete prilagoditve odmerkov, manjše od 1 mg, se posvetujte z zdravnikom, ali lahko uporabljate zdravilo EXUBERA (glejte poglavje 3 “Kako uporabljati zdravilo EXUBERA” in poglavje 6 “Dodatne informacije”).
In type 1 subjects, resolution of small treatment group differences (0.010L favouring comparator) occurred within 2 weeks of EXUBERA cessation following 12 weeks of therapy. 
Pri bolnikih z diabetesom tipa 1 so majhne razlike med skupinama, zdravljenima z različnima zdraviloma (0,010 L v korist primerjalnega zdravila), izginile v dveh tednih po ukinitvi zdravila EXUBERA po 12 tednih zdravljenja.
There has also been 1 post-marketing report of a primary lung malignancy in an Exubera-treated patient. 
V pomarketinškim obdobju je bil opisan 1 primer primarnega malignoma pljuč pri bolniku, zdravljenem z zdravilom EXUBERA.
Squeeze the two chamber release buttons at the same time on the side of the base. 
Hkrati stisnite oba gumba za sproščanje komore, ki sta ob straneh podnožja.
Both EXUBERA and comparator treated subjects experienced declines in lung function over time during these trials (Figures 2 and 3). 
Tako pri bolnikih, zdravljenih z zdravilom EXUBERA, kot pri bolnikih, zdravljenih s primerjalnim zdravilom, se je med temi preskušanjih sčasoma zmanjšala pljučna funkcija (sliki 2 in 3).
EXUBERA should not be taken during pregnancy. 
Zdravila EXUBERA med nosečnostjo ne smete jemati.
In this case you must change the Insulin Release Unit (IRU) prior to your 
V tem primeru morate pred naslednjo inhalacijo nastavek za sproščanje insulina (Insulin release unit - IRU) zamenjati.
The intra-subject variability of glucose lowering activity of inhaled human insulin was generally comparable to that of subcutaneously administered fast-acting human insulin in subjects with type 1 
Variabilnost aktivnosti zniževanja glukoze humanega insulina za inhaliranje je bila na splošno primerljiva s tisto pri subkutano apliciranem hitrodelujočem humanem insulinu pri bolnikih z
In patients with hepatic or renal impairment insulin requirements may be diminished. 
Okvare jeter in ledvic Pri bolnikih z okvaro jeter ali ledvic utegnejo biti potrebe po insulinu zmanjšane.
For instructions on how to attach the chamber to the base refer to the section “Put your insulin 
Za navodila, kako sestaviti komoro s podnožjem, glejte poglavje “Sestavite insulinski inhalator”.
There is no experience on the use of EXUBERA in pregnant women. 
Z uporabo zdravila EXUBERA pri nosečnicah ni izkušenj.
Observed Change from Baseline in FEV1 (L) in patients with type 2 diabetes mellitus. 
Opažena sprememba FEV1 (L) od izhodišča pri bolnikih z diabetesom mellitusom tipa 2.
The bottom of the chamber MUST be above the grey button. 
Spodnji rob komore MORA biti
In type 2 subjects, resolution of small treatment group differences (0.039L favouring comparator) occurred within 6 weeks of EXUBERA cessation following 2 years of therapy (Figure 3). 
Pri bolnikih z diabetesom tipa 2 so majhne razlike med skupinama, zdravljenima z različnima zdraviloma (0,039 L v korist primerjalnega zdravila), izginile v šestih tednih po ukinitvi zdravila EXUBERA po 2 letih zdravljenja (slika 3).
When an EXUBERA treated patient becomes pregnant appropriate subcutaneous insulin should be substituted for inhaled insulin. 
Če bolnica, ki uporablja EXUBERO, zanosi, je treba EXUBERO nadomestiti z ustreznim subkutanim insulinom.
If the insulin inhaler is inadvertently exposed to extremely moist conditions during use this usually leads to a subsequent decreased the insulin dose delivered from the inhaler. 
Če je insulinski inhalator med uporabo po nepazljivosti izpostavljen izredno vlažnemu okolju, to najverjetneje povzroči, da sprosti manjši odmerek insulina.
The IRU must be changed after accidental exposure to extremely moist conditions, e.g. steamy bathroom. 
Prav tako ga morate zamenjati tudi po naključni izpostavitvi inhalatorja izredno vlažnemu okolju, npr. v
There is no clinical experience with EXUBERA use in pregnancy. 
Z uporabo zdravila EXUBERA med nosečnostjo ni kliničnih izkušenj.
Inform your doctor or nurse if you are planning to become pregnant or if you are already pregnant. 
Če nameravate zanositi ali ste že noseči, o tem obvestite zdravnika ali medicinsko sestro.
A 1 mg unit dose blister is approximately equal to 3 IU of fast-acting subcutaneous insulin and a 3 mg unit dose blister is approximately equal to 8 IU of fast-acting subcutaneous insulin. 
1-mg enoodmerni pretisni omot ustreza približno 3 i.e. hitrodelujočega subkutanega insulina, 3-mg enoodmerni pretisni omot pa 8 i.e. hitrodelujočega subkutanega insulina.
A decline from baseline in FEV1 of > 15% occurred in 1.3% of EXUBERA-treated and 1.0% of comparator-treated type 1 subjects and in 5.0% of EXUBERA-treated and 3.4% of comparator-treated 
Pri bolnikih z diabetesom tipa 1 se je zmanjšanje FEV1 za > 15 % od izhodišča pojavilo pri 1,3 % bolnikov, zdravljenih z zdravilom EXUBERA, in pri 1,0 % bolnikov, zdravljenih s primerjalnim zdravilom; pri bolnikih z diabetesom tipa 2 se je takšno zmanjšanje FEV1 pojavilo pri 5,0 % bolnikov, zdravljenih z zdravilom EXUBERA, in pri 3,4 % bolnikov, zdravljenih s primerjalnim zdravilom.
Each unit dose blister contains 1 mg or 3 mg of the active substance insulin human. 
En enoodmerni pretisni omot vsebuje 1 mg ali 3 mg zdravilne učinkovine, humanega insulina.
oC. Store in the original package in order to protect from moisture. 
Shranjujte pri temperaturi do 30o C. Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago.
Your blood sugar levels may fall too much, if for example: - you take too much insulin, - you miss meals or delay them, - you do not eat enough, or eat food containing less carbohydrate than normal (sugar and substances similar to sugar are called carbohydrates; however, artificial sweeteners are NOT carbohydrates), - you lose or are unable to consume carbohydrates due to vomiting or diarrhoea, - you drink alcohol, particularly if you are not eating much, - you take more physical exercise than usual or a different type of physical activity, - you are recovering from an injury or operation or other stress, - you are recovering from a feverish illness or from another illness, - you are taking or have stopped taking certain other medicines (see section 2, “Taking other 
- izgubljate ali ne morete uživati ogljikovih hidratov zaradi bruhanja ali driske, - pijete alkohol, posebno še, če ne jeste veliko, - ste telesno bolj aktivni kot običajno ali je vaša telesna aktivnost drugačne vrste, - okrevate po poškodbi, operaciji ali kakem drugem stresu, - okrevate po vročinski bolezni ali kakšni drugi bolezni, - jemljete ali ste prenehali jemati nekatera druga zdravila (glejte poglavje 2 “Jemanje drugih zdravil”).
The exposure of human insulin following administration of three 1 mg blisters is significantly greater than that following a single 3 mg blister. 
Izpostavljenost humanemu insulinu je po uporabi treh 1-mg pretisnih omotov bistveno večja kot po uporabi enega samega 3-mg pretisnega omota.
Randomised, open label parallel group studies were conducted to examine FEV1 changes following initiation of EXUBERA therapy in type 1 and 2 subjects. 
Za raziskovanje sprememb FEV1 po uvedbi zdravljenja z zdravilom EXUBERA pri bolnikih z diabetesom tipa 1 in tipa 2 so opravili randomizirane odprte študije s paralelnimi skupinami.
Renal impairment 
Okvare ledvic
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton/Unit dose blisters (60, 90, 180, 270) 
PODATKI NA ZUNANJI OVOJNINI Škatla / enoodmerni pretisni omoti ( 60, 90, 180, 270)
In Phase 2/3 trials, 9 out of 2498 subjects treated with EXUBERA were discontinued from trials due to a decline in pulmonary function whose end of study FEV1 showed a decline of ≥ 15% from baseline. 
V študijah 2. in 3. faze so zaradi poslabšanja pljučne funkcije (zmanjšanje FEV1 za 15 % ali več) prekinili terapijo pri devetih izmed 2498 oseb, ki so prejemali EXUBERO.
A decline from baseline in FEV1 of > 15% occurred in 1.3% of EXUBERA-treated type 1 subjects and in 5.0% of EXUBERA-treated type 2 subjects. 
Zmanjšanje FEV1 za > 15 % od izhodišča se je pojavilo pri bolnikih z diabetesom tipa 1 pri 1,3 % bolnikov, zdravljenih z zdravilom EXUBERA, pri bolnikih z diabetesom tipa 2 pa pri 5,0 % bolnikov.
Fasting plasma glucose was similar to or lower in patients using a regimen including EXUBERA compared to patients treated with oral agents alone. 
Plazemska glukoza na tešče je bila podobna ali nižja pri bolnikih, ki so uporabljali shemo, ki je vključevala zdravilo EXUBERA, kot pri bolnikih, zdravljenih samo s peroralnimi antidiabetiki.
Educational material shall consist of information aiming to minimise adverse events and support effective use through adequate education about: 
Izobraževalna gradiva bodo obsegala informacije, namenjene minimizaciji neželenih dogodkov in bodo pripomogla k učinkoviti uporabi z ustreznim informiranjem o: a) potrebi po doslednem in standardnem načinu inhaliranja, ki naj zagotovi optimalen in b) posebnih previdnostnih ukrepih z inhalatorjem insulina,
(Seen in more than 1 in 10 patients) 
Neželeni učinki, o katerih poročajo zelo pogosto (Pojavijo se pri več kot 1 od 10 bolnikov)
Hold the insulin inhaler in your hand. 
Pripravite insulinski inhalator Držite insulinski inhalator v roki.
You should also tell your doctor if you develop any other increasing breathing difficulties while 
Zdravniku morate povedati, če se vam med uporabo zdravila EXUBERA pojavijo kakšne druge
Each unit dose blister contains 1 mg insulin human. 
En enoodmerni pretisni omot vsebuje 1 mg humanega insulina.
Three 1 mg blisters should not be substituted for one 3 mg blister (see section 2, “Take special care with EXUBERA” and section 3, “How to take EXUBERA”). 
Enega 3-mg pretisnega omota ne smete nadomestiti s tremi 1-mg (glejte poglavje 2 “Bodite posebno pozorni pri uporabi zdravila EXUBERA” in poglavje 3 “Kako uporabljati
Changes to your sight may occur upon starting insulin therapy. 
Po začetku zdravljenja z insulinom se lahko pojavijo spremembe vida.
Consecutive inhalation of three 1 mg unit dose blisters causes a significantly higher insulin exposure than inhalation of one 3 mg unit dose blister. 
Zaporedno inhaliranje treh 1-mg pretisnih omotov za enkratni odmerek povzroči bistveno večjo izpostavljenost insulinu kot inhaliranje enega 3-mg pretisnega omota za enkratni odmerek.
If you accidentally expose your inhaler to moist conditions during use, this will usually decrease the dose of insulin you take. 
Če inhalator med uporabo po nesreči izpostavite vlažnemu okolju, to ponavadi zmanjša vnešeni odmerek insulina.
Fasting plasma glucose levels were significantly lower in patients treated with EXUBERA regimens compared with those treated with subcutaneous insulin. 
Koncentracije plazemske glukoze na tešče so bile pomembno nižje pri bolnikih, zdravljenih s shemami z zdravilom EXUBERA, kot pri bolnikih, zdravljenih s subkutanim insulinom.
Three 1 mg unit dose blisters should not be substituted for one 3mg blister (see section 2, “Take special care with EXUBERA”, section 3, “How to take EXUBERA” and section 6 
Enega 3-mg pretisnega omota ne smete nadomestiti s tremi 1-mg pretisnimi omoti (glejte poglavje 2 “Bodite posebno pozorni pri uporabi zdravila EXUBERA”, poglavje 3 “Kako uporabljati zdravilo EXUBERA” in poglavje 6 “Dodatne informacije”).
Turn the used IRU about a one-quarter turn counter clockwise towards the unlock symbol. 
Zasukajte rabljeni nastavek za sproščanje insulina za približno četrt obrata v smeri, nasprotni od smeri urnega kazalca, proti
For the 3 mg product, the spine of the blister card has three raised ridges with the individual blisters embossed with three raised dots each. 
Pri jakosti 3 mg ima hrbtišče ploščice s pretisnimi omoti tri podolgovate izbokline, vsak od posamičnih pretisnih omotov pa po tri izbočene točke.
There is little experience with EXUBERA in patients older than 75 years. 
Pri bolnikih, starejših od 75 let, imamo z zdravilom EXUBERA malo izkušenj.
If you have low body weight check with your doctor if you can use EXUBERA. 
Če imate nizko telesno maso ali potrebujete prilagoditve odmerkov, manjše od 1 mg, se posvetujte z zdravnikom, ali lahko uporabljate zdravilo EXUBERA.
6.4 Special precautions for storage Store below 30 
6.4 Posebna navodila za shranjevanje
Table 1 above presents the approximate IU dose of fast-acting human insulin for initial, pre-meal EXUBERA doses in mg. 
Preglednica 1 prikazuje približno enakovreden odmerek v i.e. hitrodelujočega humanega insulina za začetne odmerke EXUBERE pred
HOW TO TAKE EXUBERA 
Kako se pripravite, da boste vzeli zdravilo EXUBERA